It implies that maintaining the expression of YAP/TAZ, which can be implemented by YAP/TAZ/TEAD1 activators or inhibitors of upstream kinases (MST1/2, LATS1/2), maybe a potential target in future diabetes treatment. This evidence concerns the gene MST1 and diabetes mellitus.